187 related articles for article (PubMed ID: 37303063)
21. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
[TBL] [Abstract][Full Text] [Related]
22. Silencing of Perilipin 3 Inhibits Lung Adenocarcinoma Cell Immune Resistance by Regulating the Transcription of PD-L1 Through c-Myc.
Men X; Zhu W
Immunol Invest; 2023 Nov; 52(7):815-831. PubMed ID: 37578465
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma.
Huang J; Weng Q; Shi Y; Mao W; Zhao Z; Wu R; Ren J; Fang S; Lu C; Du Y; Ji J
FEBS Open Bio; 2020 Jun; 10(6):1065-1071. PubMed ID: 32237066
[TBL] [Abstract][Full Text] [Related]
24. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.
Zhu J; Wang W; Xiong Y; Xu S; Chen J; Wen M; Zhao Y; Lei J; Jiang T
Cancer Med; 2023 Mar; 12(5):5545-5557. PubMed ID: 36325966
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma.
Zhang Y; Du W; Chen Z; Xiang C
Exp Cell Res; 2017 Oct; 359(2):449-457. PubMed ID: 28830685
[TBL] [Abstract][Full Text] [Related]
27. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
28. Dysregulated ferroptosis-related genes indicate potential clinical benefits for anti-PD-1/PD-L1 immunotherapy in lung adenocarcinoma.
Zhou M; Zhang X; Li T; Chen Y
J Clin Lab Anal; 2021 Dec; 35(12):e24086. PubMed ID: 34752672
[TBL] [Abstract][Full Text] [Related]
29. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.
Yang P; He S; Ye L; Weng H
Int Arch Allergy Immunol; 2024 May; ():1-11. PubMed ID: 38781935
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of PD-L1 expression, tumor-infiltrating lymphocytes, and tumor microenvironment in LUAD: differences between Asians and Caucasians.
Bie F; Tian H; Sun N; Zang R; Zhang M; Song P; Liu L; Peng Y; Bai G; Zhou B; Gao S
Clin Epigenetics; 2021 Dec; 13(1):229. PubMed ID: 34933667
[TBL] [Abstract][Full Text] [Related]
31. Involvement of ZDHHC9 in lung adenocarcinoma: regulation of PD-L1 stability via palmitoylation.
Li Z; Jiang D; Liu F; Li Y
In Vitro Cell Dev Biol Anim; 2023 Mar; 59(3):193-203. PubMed ID: 37002491
[TBL] [Abstract][Full Text] [Related]
32. ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma.
Qu T; Zhang W; Yan C; Ren D; Wang Y; Guo Y; Guo Q; Wang J; Liu L; Han L; Li L; Huang Q; Cao L; Ye Z; Zhang B; Zhao Q; Cao W
J Transl Med; 2023 May; 21(1):341. PubMed ID: 37217923
[TBL] [Abstract][Full Text] [Related]
33. Expression of PD-L1 through evolution phase from pre-invasive to invasive lung adenocarcinoma.
Zhou J; Lin H; Ni Z; Luo R; Yang D; Feng M; Zhang Y
BMC Pulm Med; 2023 Jan; 23(1):18. PubMed ID: 36647116
[TBL] [Abstract][Full Text] [Related]
34. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
35. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Zhou F; Wang X; Liu F; Meng Q; Yu Y
Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
[TBL] [Abstract][Full Text] [Related]
37. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Guo CY; Zhu Q; Tou FF; Wen XM; Kuang YK; Hu H
BMC Cancer; 2019 Mar; 19(1):289. PubMed ID: 30925904
[TBL] [Abstract][Full Text] [Related]
38. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
39. An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development.
Wang Q; Xie B; Sun J; Li Z; Xiao D; Tao Y; She X
J Cancer; 2024; 15(6):1687-1700. PubMed ID: 38370388
[No Abstract] [Full Text] [Related]
40. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
